Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09), Briefing.com reports. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The business had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. During the same quarter in the prior year, the firm posted ($1.51) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was up 28.4% compared to the same quarter last year.

Agios Pharmaceuticals Trading Down 1.2 %

AGIO opened at $43.96 on Friday. Agios Pharmaceuticals has a 1-year low of $19.80 and a 1-year high of $50.35. The stock’s fifty day simple moving average is $44.48 and its 200 day simple moving average is $34.47. The stock has a market cap of $2.50 billion, a PE ratio of -6.96 and a beta of 0.79.

Wall Street Analysts Forecast Growth

AGIO has been the subject of a number of recent research reports. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 11th. Royal Bank of Canada upped their price target on Agios Pharmaceuticals from $53.00 to $55.00 and gave the stock an “outperform” rating in a research report on Friday. The Goldman Sachs Group upped their price objective on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $51.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.